US Stock MarketDetailed Quotes

GALT Galectin Therapeutics

Watchlist
  • 1.410
  • +0.110+8.46%
Close Feb 14 16:00 ET
  • 1.480
  • +0.070+4.96%
Post 20:01 ET
88.49MMarket Cap-1.93P/E (TTM)

About Galectin Therapeutics Company

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.

Company Profile

SymbolGALT
Company NameGalectin Therapeutics
Listing DateSep 10, 2003
Founded2000
CEOMr. Joel Lewis
MarketNASDAQ
Employees14
Fiscal Year Ends12-31
Address4960 Peachtree Industrial Boulevard,Suite 240
CityNorcross
ProvinceGeorgia
CountryUnited States of America
Zip Code30071
Phone1-678-620-3186

Company Executives

  • Name
  • Position
  • Salary
  • Joel Lewis
  • Director, President and Chief Executive Officer
  • 963.65K
  • Jack W. Callicutt
  • Chief Financial Officer and Principal Accounting Officer
  • 561.42K
  • Dr. Khurram Jamil
  • Chief Medical Officer
  • --
  • Richard E. Uihlein
  • Chairman of the Board
  • 71.74K
  • Dr. Benjamin S. Carson,Sr,M.D.
  • Director
  • 2.72K
  • Dr. Marc Rubin,M.D.
  • Independent Director
  • 75.24K
  • Kevin D. Freeman
  • Independent Director
  • 87.74K
  • Richard A. Zordani
  • Independent Director
  • 86.74K
  • Kary Eldred
  • Independent Director
  • 79.24K
  • Dr. Gilbert S. Omenn,M.D.,PhD
  • Independent Director
  • 81.74K
  • Dr. Gilbert F. Amelio,PhD
  • Independent Director
  • 87.24K
  • Dr. Harold H. Shlevin,PhD
  • Independent Director
  • 71.74K
  • Dr. Elissa J. Schwartz, PhD
  • Independent Director
  • 75.24K

Trending Stocks

Discussing
Big Tech’s earnings season in full swing! Nvidia is the only one left
On Thursday, $Amazon (AMZN.US)$ stock fell after the firm reported Q4 adjusted earnings of $1.86/share, vs estimates of $1.50/share, on reve Show More